A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011
NCT06354114 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80
Last updated 2024-04-09
Summary
The main purpose of this study is to evaluate the efficacy and safety in subjects with advanced breast cancer treated with SYHX2011
Conditions
Interventions
- DRUG
-
SYHX2011
IV infusion, 260 mg/m\^2
Sponsors & Collaborators
-
CSPC Ouyi Pharmaceutical Co., Ltd.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-04-30
- Primary Completion
- 2024-10-31
- Completion
- 2026-12-31
Countries
- China
Study Locations
More Related Trials
-
Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer
NCT05860465 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors
NCT07122063 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
NCT04890613 ·Status: RECRUITING ·Phase: PHASE1
-
Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer
NCT07180056 ·Status: RECRUITING
-
Study of Irinotecan Liposome Injection in Patients With Advanced Breast Cance
NCT04728035 ·Status: COMPLETED ·Phase: PHASE1
-
SHR-1811 Combined With Carboplatin in the Treatment of Advanced Breast Cancer With HER2 Expression
NCT07047443 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors
NCT07156253 ·Status: RECRUITING ·Phase: PHASE1
-
Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors
NCT06929325 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer
NCT05519059 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.
NCT05845138 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors
NCT06503783 ·Status: RECRUITING ·Phase: PHASE1
-
Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation
NCT06970132 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer
NCT06340230 ·Status: RECRUITING ·Phase: PHASE2
-
Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer
NCT06344780 ·Status: ACTIVE_NOT_RECRUITING
-
Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer
NCT06413745 ·Status: RECRUITING ·Phase: PHASE2
-
A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer
NCT05353361 ·Status: RECRUITING ·Phase: PHASE2
-
CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer
NCT05795335 ·Status: RECRUITING
-
Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases
NCT05769010 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
NCT05635487 ·Status: RECRUITING ·Phase: PHASE2
-
DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer
NCT05334810 ·Status: UNKNOWN ·Phase: PHASE2
-
Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer
NCT02499146 ·Status: COMPLETED ·Phase: PHASE1
-
An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer
NCT05186545 ·Status: UNKNOWN ·Phase: PHASE2
-
Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer Patients
NCT06592625 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Irinotecan for Advanced and Metastatic Breast Cancer
NCT03562390 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.
NCT05792410 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2